S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10

Acurx Pharmaceuticals Stock Forecast, Price & News

-0.18 (-3.60 %)
(As of 10/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume50,199 shs
Average Volume268,596 shs
Market Capitalization$48.77 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ACXP News and Ratings via Email

Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.


Acurx Pharmaceuticals to Join the Russell Microcap Index®
September 2, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales





Market Cap
$48.77 million
Next Earnings Date
11/15/2021 (Estimated)
Not Optionable


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1335th out of 1,359 stocks

Pharmaceutical Preparations Industry

653rd out of 666 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Acurx Pharmaceuticals (NASDAQ:ACXP) Frequently Asked Questions

What stocks does MarketBeat like better than Acurx Pharmaceuticals?

Wall Street analysts have given Acurx Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Acurx Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Acurx Pharmaceuticals?

Acurx Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 96,200 shares, an increase of 24.9% from the August 31st total of 77,000 shares. Based on an average daily volume of 548,800 shares, the short-interest ratio is presently 0.2 days.
View Acurx Pharmaceuticals' Short Interest

When is Acurx Pharmaceuticals' next earnings date?

Acurx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Acurx Pharmaceuticals

How were Acurx Pharmaceuticals' earnings last quarter?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) released its quarterly earnings results on Monday, August, 16th. The company reported ($0.57) EPS for the quarter.
View Acurx Pharmaceuticals' earnings history

Who are Acurx Pharmaceuticals' key executives?

Acurx Pharmaceuticals' management team includes the following people:
  • Mr. Robert J. DeLuccia, Co-Founder & Exec. Chairman (Age 75, Pay $342.75k)
  • Mr. David P. Luci C.P.A., CPA, J.D., Esq., Co-Founder, Pres, CEO & Director (Age 54, Pay $321.21k)
  • Mr. Robert G. Shawah, Co-Founder, CFO & Chief Accounting Officer (Age 54, Pay $90k)

When did Acurx Pharmaceuticals IPO?

(ACXP) raised $15 million in an IPO on Friday, June 25th 2021. The company issued 2,500,000 shares at a price of $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities acted as the underwriters for the IPO.

What is Acurx Pharmaceuticals' stock symbol?

Acurx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACXP."

When does the company's lock-up period expire?

Acurx Pharmaceuticals' lock-up period expires on Wednesday, December 22nd. Acurx Pharmaceuticals had issued 2,500,000 shares in its IPO on June 25th. The total size of the offering was $15,000,000 based on an initial share price of $6.00. After the end of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

How do I buy shares of Acurx Pharmaceuticals?

Shares of ACXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acurx Pharmaceuticals' stock price today?

One share of ACXP stock can currently be purchased for approximately $4.82.

How much money does Acurx Pharmaceuticals make?

Acurx Pharmaceuticals has a market capitalization of $48.77 million.

How many employees does Acurx Pharmaceuticals have?

Acurx Pharmaceuticals employs 3 workers across the globe.

What is Acurx Pharmaceuticals' official website?

The official website for Acurx Pharmaceuticals is www.acurxpharma.com.

How can I contact Acurx Pharmaceuticals?

The company can be reached via phone at 917-533-1469.

This page was last updated on 10/24/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.